4
Changes in Ownership
HALOZYME THERAPEUTICS, INC. Filed Acc 0001415889-24-023307
PRESIDENT AND CEO sold 30,000 shares at an average $59.13 ($1,773,790)
- PRESIDENT AND CEO acquired 30,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Torley Helen · PRESIDENT AND CEO
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-09-10 | Exercise or conversion : show line 1 in the form 10b5-1 | +10,000 | $13.87 | $138,700 | 686,744 | D |
| 2024-09-10 | Sale : show line 2 in the form 10b5-1 | −10,000 | $59.09 | $590,890 | 676,744 | D |
| 2024-09-11 | Exercise or conversion : show line 3 in the form 10b5-1 | +10,000 | $13.87 | $138,700 | 686,744 | D |
| 2024-09-11 | Sale : show line 4 in the form 10b5-1 | −10,000 | $59.09 | $590,870 | 676,744 | D |
| 2024-09-12 | Exercise or conversion : show line 5 in the form 10b5-1 | +10,000 | $13.87 | $138,700 | 686,744 | D |
| 2024-09-12 | Sale : show line 6 in the form 10b5-1 | −10,000 | $59.20 | $592,030 | 676,744 | D |
| Open-market sales · 30,000 sh · avg $59.13 · $1,773,790 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-09-10 | Exercise or conversion : show line 7 in the form 10b5-1 Option to Purchase Common Stock | −10,000 | $13.87 | $138,700 | 70,000 | D |
| 2024-09-11 | Exercise or conversion : show line 8 in the form 10b5-1 Option to Purchase Common Stock | −10,000 | $13.87 | $138,700 | 60,000 | D |
| 2024-09-12 | Exercise or conversion : show line 9 in the form 10b5-1 Option to Purchase Common Stock | −10,000 | $13.87 | $138,700 | 50,000 | D |
Loading xslF345X05/form4-09122024_090954.xml…